Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00254878 | Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14 | PHASE3 | COMPLETED | 130 | — | — | Oct 1, 2005 | Feb 1, 2006 | Dec 21, 2007 | 1 | Germany |
| Name | Type | Description |
|---|---|---|
| Methylphenidate hydrochloride | DRUG | - |
Inclusion Criteria: Patients who meet all of the following inclusion criteria will be eligible for enrollment in the study: * Male and female patients aged 6-14. * Patients having a diagnosis of ADHD of any type according to DSM-IV criteria, as established by history, psychiatric examination and a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |